These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
242 related articles for article (PubMed ID: 12907552)
1. Clinical equivalence of two cytokeratin markers in mon-small cell lung cancer: a study of tissue polypeptide antigen and cytokeratin 19 fragments. Buccheri G; Torchio P; Ferrigno D Chest; 2003 Aug; 124(2):622-32. PubMed ID: 12907552 [TBL] [Abstract][Full Text] [Related]
2. Correlation between serum cytokeratin 19 fragment and tissue polypeptide antigen levels in patients with non-small cell lung cancer. Kashiwabara K; Nakamura H; Kiguchi T; Yagyu H; Kishi K; Wei BR; Yoneyama K; Matsuoka K Clin Chim Acta; 1997 Oct; 266(2):149-55. PubMed ID: 9437543 [TBL] [Abstract][Full Text] [Related]
3. Cyfra 21-1, neuron specific enolase and prognosis of non-small cell lung cancer: prospective study in 621 patients. Pujol JL; Boher JM; Grenier J; Quantin X Lung Cancer; 2001; 31(2-3):221-31. PubMed ID: 11165401 [TBL] [Abstract][Full Text] [Related]
4. Cyfra 21-1 in monitoring cervical cancer: a comparison with tissue polypeptide antigen and squamous cell carcinoma antigen. Bonfrer JM; Gaarenstroom KN; Korse CM; Van Bunningen BN; Kenemans P Anticancer Res; 1997; 17(3C):2329-34. PubMed ID: 9245246 [TBL] [Abstract][Full Text] [Related]
5. Tumour markers CEA, NSE, SCC, TPA and CYFRA 21.1 in resectable non-small cell lung cancer. Foa P; Fornier M; Miceli R; Seregni E; Santambrogio L; Nosotti M; Cataldo I; Sala M; Caldiera S; Bombardieri E Anticancer Res; 1999; 19(4C):3613-8. PubMed ID: 10629660 [TBL] [Abstract][Full Text] [Related]
6. Comparison of cytokeratin fragment 19 (CYFRA 21-1), tissue polypeptide antigen (TPA) and carcinoembryonic antigen (CEA) as tumour markers in bronchogenic carcinoma. Huang MS; Jong SB; Tsai MS; Lin MS; Chong IW; Lin HC; Hwang JJ Respir Med; 1997 Mar; 91(3):135-42. PubMed ID: 9135852 [TBL] [Abstract][Full Text] [Related]
7. Prognostic value of serum tumor markers in patients with lung cancer. Hatzakis KD; Froudarakis ME; Bouros D; Tzanakis N; Karkavitsas N; Siafakas NM Respiration; 2002; 69(1):25-9. PubMed ID: 11844959 [TBL] [Abstract][Full Text] [Related]
8. Evaluation of tissue polypeptide specific antigen, CYFRA 21-1, and carcinoembryonic antigen in nonsmall cell lung carcinoma: does the combined use of cytokeratin markers give any additional information? Nisman B; Lafair J; Heching N; Lyass O; Baras M; Peretz T; Barak V Cancer; 1998 May; 82(10):1850-9. PubMed ID: 9587116 [TBL] [Abstract][Full Text] [Related]
9. Serum biomarkers facilitate the recognition of early- stage cancer and may guide the selection of surgical candidates: a study of carcinoembryonic antigen and tissue polypeptide antigen in patients with operable non-small cell lung cancer. Buccheri G; Ferrigno D J Thorac Cardiovasc Surg; 2001 Nov; 122(5):891-9. PubMed ID: 11689793 [TBL] [Abstract][Full Text] [Related]
10. Clinical value of pretreatment serum Cyfra 21-1, tissue polypeptide antigen, and squamous cell carcinoma antigen levels in patients with cervical cancer. Gaarenstroom KN; Bonfrer JM; Kenter GG; Korse CM; Hart AA; Trimbos JB; Helmerhorst TJ Cancer; 1995 Sep; 76(5):807-13. PubMed ID: 8625184 [TBL] [Abstract][Full Text] [Related]
11. Cyfra 21-1 as a biologic marker of non-small cell lung cancer. Evaluation of sensitivity, specificity, and prognostic role. Wieskopf B; Demangeat C; Purohit A; Stenger R; Gries P; Kreisman H; Quoix E Chest; 1995 Jul; 108(1):163-9. PubMed ID: 7541742 [TBL] [Abstract][Full Text] [Related]
12. High preoperative and postoperative levels of carcinoembryonic antigen and CYFRA 21-1 indicate poor prognosis in patients with pathological Stage I nonsmall cell lung cancer. Duan X; Cui Y; Li H; Shi G; Wu B; Liu M; Chang D; Wang T; Kong Y Indian J Cancer; 2015 Dec; 52 Suppl 3():E158-63. PubMed ID: 27453414 [TBL] [Abstract][Full Text] [Related]
13. Elevated serum levels of TPS and CYFRA 21-1 predict poor prognosis in advanced non-small-cell lung cancer patients treated with gefitinib. Chen F; Luo X; Zhang J; Lu Y; Luo R Med Oncol; 2010 Sep; 27(3):950-7. PubMed ID: 19830603 [TBL] [Abstract][Full Text] [Related]